Botulinum toxin (BoNT) is a well established treatment in cerebral palsy. A uniform dose
strategy is, however, missing. We reviewed 35 children with spastic cerebral palsy treated …

INTRODUCTION: Cerebral palsy is the most common cause of physical disability in children.
Spasticity is a disabling clinical symptom that is prevalent among patients suffering from …

Aims: In this study the aim was to evaluate the effect of botulinum toxin A (BoNT‐A) treatment
on muscle tone, contracture development and gait pattern in young children with cerebral …

Over the past 5 years a number of studies of the use of Botulinum toxin A in the management
of cerebral palsy have been conducted. Overall 105 children, with a mean age of 6 years …

One of the main goals when treating spasticity is to relieve pain and improve function.
Intramuscular injection of botulinum toxin type A (BTX‐A) has gained widespread …

Cerebral palsy (CP) is a severely debilitating condition. The underlying insult results in
irreversible damage to the central nervous system, treatment is essentially palliative …

Background Botulinum Toxin type-A (BoNT-A) is a safe and effective treatment for reducing
spasticity in children with cerebral palsy (CP). BoNT-A injection into the muscles alleviate …

Botulinum toxin type A (BoNT-A) is considered the gold standard for the treatment of focal
post-stroke spasticity (PSS). However, a recently published study estimated that a significant …

Botulinum toxin A (BTXA), an acetylcholine-blocking chemical denervant when injected into
a muscle, has been used since 1993 in the management of spasticity in children with …

OBJECTIVE: To determine safety of intramuscular botulinum toxin A (BoNT-A) injections to
reduce spasticity and improve care and comfort of nonambulatory children with cerebral …